What is the current market size and future outlook for the postpartum depression market?
The postpartum depression market size has grown exponentially in recent years. It will grow from $12.15 billion in 2024 to $16.09 billion in 2025 at a compound annual growth rate (CAGR) of 32.4%. The growth in the historic period can be attributed to maternal mental health awareness, research advancements, public health initiatives, increased screenings.
The postpartum depression market size is expected to see exponential growth in the next few years. It will grow to $49.4 billion in 2029 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to telehealth services, pharmacological advancements, maternal mental health legislation, mental health workforce expansion. Major trends in the forecast period include integrated care models, peer support programs, perinatal mental health apps, mental health screening tools.
Get Your Free Sample of The Global Postpartum Depression Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13024&type=smp
How have varous drivers impacted the growth of the postpartum depression market?
An increase in postpartum depression cases is expected to propel the growth of the postpartum depression market going forward. Postpartum depression is an exaggerated worry that develops after giving birth. There may be physical symptoms in addition to it. Postnatal depression and postpartum anxiety frequently coexist and in the first year after giving birth, symptoms might start at any time. Postpartum depression is frequently treated with psychotherapy, commonly known as talk therapy or mental health counselling, medication, or a combination of the two, which results in the growth of the market. For instance, in February 2022, according to the survey of 1.1 million moms conducted by the University of Virginia School of Medicine (UVA SoM), a US-based medical school, the risk of postpartum depression is highest among first-time mothers, those under 25, and mothers of twins. Among age groups, the highest self-reported rate of postpartum depression symptoms was 10% among women aged 18-24. Mothers of twins reported higher rates of postpartum depression, with 11.3% showing symptoms, compared to 8.3% of mothers with single children. Therefore, an increase in postpartum depression cases will drive the postpartum depression market.
What are the primary segments of the postpartum depression market?
The postpartum depression market covered in this report is segmented –
1) By Types: Postpartum Blues, Postpartum Anxiety, Postpartum Obsessive Compulsive Disorder, Postpartum Panic Disorder, Postpartum Post-Traumatic Stress Disorder, Postpartum Psychosis, Other Types
2) By Treatment: Psychotherapy, Medication, Supplements, Other Treatments
3) By Route of Administration: Oral, Parenteral, Other Route Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Postpartum Blues: Mild Emotional Disturbances, Short-term Mood Swings
2) By Postpartum Anxiety: Generalized Anxiety Disorder (GAD), Panic Attacks
3) By Postpartum Obsessive Compulsive Disorder: Intrusive Thoughts, Compulsive Behaviors
4) By Postpartum Panic Disorder: Sudden Panic Attacks, Physical Symptoms
5) By Postpartum Post-Traumatic Stress Disorder (PTSD): Trauma Response To Childbirth, Flashbacks And Anxiety
6) By Postpartum Psychosis: Hallucinations, Severe Mood Swings
7) By Other Types: Mixed Mood Disorders, Comorbid Conditions With Postpartum
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report
Which firms are leading the postpartum depression market?
Major companies operating in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Viatris Inc., Northwell Health, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals PLC, Sage Therapeutics Inc.
How will industry trends affect the trajectory of the postpartum depression market?
Companies operating in the postpartum depression market are working on new product innovations to sustain their position in the market. The limited treatment choices have led to an increasing innovation need for faster-acting therapies and creative care delivery for postpartum depression. For instance, in February 2023, Biogen Inc., a US-based biotechnology company and Sage Therapeutics Inc., a US-based biopharmaceutical company, announced that the United States Food and Drug Administration (FDA) has accepted the filing of an NDA (new drug application) for zuranolone in the management of the major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an experimental medication that is being tested as a 14-day, once-daily, rapid-acting oral therapy in people with MDD and PPD. Zuranolone, a neuroactive steroid, acts as a positive allosteric modulator of GABA-A receptors, which is a unique method of action. It is supposed to operate in persons with depression by swiftly resetting dysregulated neural networks to help restore brain function. Zuranolone affects brain networks that control mood, arousal, behavior and even cognition.
Which geographic trends are shaping the postpartum depression market, and which region has the highest market share?
North America was the largest region in the postpartum depression market in 2024. The regions covered in postpartum depression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Postpartum Depression Market Report 2025 Offer?
The postpartum depression market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Postpartum depression (PPD) refers to a condition, which is a type of mood disorder that affects some women after giving birth and can remain undiagnosed for long periods of time. It is characterized by feelings of sadness, hopelessness and a lack of interest or pleasure in once-enjoyable activities.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13024
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
